CLL geassocieerde studies

Open studies

 Naam M18-803 T-PLL
 Titel A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-Cell Prolymphocytic Leukemia
 Referentie Clinicaltrials.gov: NCT03873493
 Status Open
 Deelnemers M. Bellido, Universitair Medisch Centrum, Groningen; m.bellido@umcg.nl
L. Tick, Maxima Medisch Centrum, Eindhoven; l.Tick@mmc.nl
 Documenten In- en exclusiecriteria
Naam ACE-CL-311
Titel A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation.
Referentie Clinicaltrials.gov: NCT04008706
Status Open
Deelnemers AmsterdamUMC - location AMC – Arnon Kater
Flevoziekenhuis – Koen de Heer
Documenten Flow + Eligibility criteria
Naam ACE-CL-312
Titel A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
Referentie Clinicaltrials.gov: NCT04008706
Status Open only for patients with prior BTKi therapy (Cohort3) (Other cohorts: Treatment-naive patients and enrollment of patients with Relapsed/Refractory disease are complete)
Deelnemers Open in:
Universitair Medisch Centrum Utrecht (Utrecht) Rogier Mous (r.mous@umcutrecht.nl)
Will also be opened in:
Albert Schweitzer Ziekenhuis (Dordrecht), Mark-David Levin
HagaZiekenhuis (Den Haag), Sabina Kersting
Rijnstate Ziekenhuis (Arnhem) Ellen vd Spek
Isala Klinieken (Zwolle), Ellen Dompeling
Documenten Flow + Eligibility criteria
Up